Beam’s sickle cell therapy meets primary trial endpoint

Beam Therapeutics’ investigational gene-edited therapy for sickle cell disease met its primary efficacy endpoint in a Phase 1/2 clinical trial, bringing the company closer to a planned FDA submission. The biotech said Nov. 10 that its BEACON study of ristoglogene autogetemcel, or risto-cel, achieved its primary endpoint of freedom from severe vaso-occlusive crises for at […] The post Beam’s sickle cell therapy meets primary trial endpoint appeared first on Becker's Hospital Review | H...